Exscientia Announces Sixth Molecule Created Through Generati

Third clinical molecule from collaboration with Sumitomo Pharma to enter Phase 1 trials


DSP-2342, a dual 5-HT2A/5-HT7 antagonist to be assessed in psychiatric disease

... | May 15, 2023

Related Keywords

United States , Sumitomo Pharma , Andrew Hopkins , Twitter , Bristol Myers Squibb , Sumitomo Pharma Co Ltd , Nasdaq , Chief Executive Officer , Bristol Myers , Exscientia Plc Stock Exchange , News , Information , Press Release , Third , Linical , Olecule , Rom , Collaboration , Ith , Sumitomo , Dharma , O , Winter , Hase , , Ual , Antagonist , The , Zpossessed , N , Sychiatric Exai Us30223g1022 ,